Design of multi-epitope, analogue-based cancer vaccines
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The current objective of our cancer programme is to develop an effective vaccine based on rationally designed T cell epitope analogues, for use in the adjuvant setting for non-small cell lung cancer (NSCLC) and colon cancer. Analogue epitopes, enhanced for either human leukocyte antigen (HLA) binding or T cell receptor (TCR) signalling, have been shown to be more effective at breaking immunological tolerance than cognate wild-type epitopes. Although encouraging early-phase clinical data has been obtained by others using a limited number of HLA-A2-restricted epitope analogues, the clinical benefits and immune correlates for vaccines comprised of multiple epitope analogues restricted by multiple HLA supertypes remains to be investigated. Clinical studies are currently being conducted on EP-2101, a prototype vaccine that delivers multiple HLA-A2-restricted analogue epitopes. In parallel, fixed anchor and heteroclitic analogues restricted by three other commonly expressed HLA supertypes are being identified. These analogues will be incorporated into future vaccines including optimised minigenes (epigenes) and tested in preclinical and clinical studies addressing various different cancer indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
Sette, A., & Sidney, J. (1999) · Immunogenetics · doi:10.1007/s002510050594 · Cited by 635 · cited 1×
“Our group has demonstrated that a large fraction of HLA class I molecules can be classified into a relatively few ‘HLA supertypes’, each characterised by largely overlapping peptide binding repertoires based on consensus structures of the main peptide binding pockets [26].”
BackgroundSelf-citation
Cited by
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
“In addition, the use of DNA libraries and protein sequence data for target epitopes that have the ability to be recognized by the human immune system have been used to identify novel epitopes for potential immunotherapy targets, such as viruses, bacteria, parasites, tumour-associated antigens or other self-antigens as…”
BackgroundHLA class I supertypes: a revised and updated classification
Sidney, J., Peters, B., Frahm, N., Brander, C., & Sette, A. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-1 · Cited by 775
Self-citationPeptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Metadata
- Authors
- Fikes, J. D., & Sette, A.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2003-09
- Volume
- 3
- Issue
- 6
- Pages
- 985-993
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2164578230
- Cited by
- 36
- References
- 1
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of multi-epitope, analogue-based cancer vaccines. https://app.cochat.ai/papers/10.1517/14712598.3.6.985
- The paper
- Fikes, J. D., & Sette, A. (2003). Design of multi-epitope, analogue-based cancer vaccines. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.3.6.985
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.